20 weeks after the second inoculation, the effect of preventing symptomatic infection of Omicron AZ 0%, Pfizer 10%
A study in the UK found that the risk of hospitalization for omicron mutations was one-third that of delta mutations.
The UK Health and Safety Agency (UKHSA) announced on the 31st (local time) that it obtained the same result by analyzing 1 million cases of Omicron mutation and delta mutation infection from November 22 to December 26 in cooperation with the University of Cambridge.
If you include emergency room treatment, the risk is only half that of the delta mutation.
According to an analysis by the Health and Safety Administration, the risk of hospitalization due to omicron mutation after the third dose of the vaccine is 81% lower than that of those who are not vaccinated.
In another study, the Health and Safety Administration said, the vaccine’s effectiveness in preventing hospitalization due to omicron mutation reached 72% up to 6 months after the second dose, 52% thereafter, and 88% two weeks after the third dose.
However, the vaccine’s effectiveness in blocking symptomatic infection is lower in the omicron mutation than in the delta mutation.
Two doses of AstraZeneca vaccine have no effect on Omicron mutation after 20 weeks.
If you get Pfizer or Moderna twice, the effect drops from 65-70% to 10% after 20 weeks.
The effect is 65-75% after 2-4 weeks after the booster shot, 55-70% after 5-9 weeks, and drops to 40-50% after 10 weeks.
Susan Hopkins, chief medical adviser for the Department of Health and Safety, said it was too early to draw any conclusions about the severity of the omicron mutation.
Hopkins also said that the omicron mutation is highly contagious and the rise in infections over the age of 60 means that it will likely place a significant strain on the health care system in the future.
British Health Minister Sajid Javid said: “The data show the importance of a vaccine.”
/yunhap news
ⓒ Hankyung.com, unauthorized reprinting and redistribution prohibited
